RESUMO
Ginsenoside Rg1 ( Rg1 ) is a monomer isolated from ginseng, which has a variety of pharmacological activities. Rg1 can obviously regulate hematopoietic stem cells, mesenchymal stem cells, neural stem cells and endothelial progenitor cells proliferation, differentiation, aging, secretion and so on by mul-tiple mechanisms. Rg1 has important therapeutic effects on the reparation of tissues, organs damage and aging. This review de-scribes the current knowledge on the effects of Rg1 on the char-acteristics and functions of adult stem cells.
RESUMO
Objective] Simply introduce the experiences of director You Jianliang using traditional Chinese medicine(TCM) to treat nasopharyngeal carcinoma (NPC), in order to more fully meet nasopharyngeal carcinoma, so as to broaden the thinking, enhance the clinical curative effect.[Method] From the etiology and pathogenesis, syndrome differentiation, treatment characteristics and medical record, etc., summing up the experiences of director You Jianliang using TCM to treat NPC from the angle of combining traditional Chinese and western medicine treatment. [Result] You Jianliang director thinks, nasopharyngeal carcinoma is a traditional Chinese medicinenasal running,wither complexion,upper stone gangrenecategory, such as the pathogenesis is characterized by the virtual to real, generally can be divided into evil poison lung heat, liver depression phlegm coagulation, qi and blood stasis, Yin fire, deficiency of qi and blood. Director, according to syndrome differentiation, especially from dryness and embellish, tapping and supplement, many inferior angle of flexible, chose medication, changed with signs to add and subtract, in order to improve the symptoms of patients, improve the quality of survival, slow disease progression. Cure is given priority to qi and nourishing Yin, and with the disease to add and subtract, now the symptoms were stable. [Conclusion] You Jianliang, director understanding of the etiology and pathogenesis of nasopharyngeal carcinoma(NPC) analysis to the solution of TCM syndrome differentiation, treatment is also unique, finishing You Jianliang treatment of nasopharyngeal carcinoma(NPC), director of the academic experience, help to confirm, in the medical record in patients with nasopharyngeal carcinoma after concurrent chemoradiation.
RESUMO
PURPOSE: We investigated the effects of recombinant 9-10th type III repeat of fibronectin (rhFNIII9-10) on the adhesion, proliferation, and the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells(hMSCs). MATERIALS AND METHODS: Adhesion and blocking assay for hMSCs were performed on the plates which had been coated with 100 microgram/ml rhFNIII9-10 or fibronectin. hMSCs seeded on the precoated plates were cultured in the osteogenic media for 3 weeks. MTS(Dimethylthiazole carboxymethoxyphenyl sulfophenyl tetrazolium compound) assay for the cell number, [Methyl-3H] thymidine incorporation study, alkaline phosphatase activity assay, calcium content assay and RT-PCR for alkaline phosphatase, osteopontin, cbfa-1, and type I collagen were performed during the osteogenic differentiation. RESULTS: hMSCs showed significantly increased adhesion to rhFNIII9-10-coated plates and fibronectin-coated plates. A monoclonal antibody to the integrin alpha 5 beta 1 inhibited adhesion to rhFNIII9-10-coated plates and fibronectin-coated plates in dose-dependent manner. hMSCs seeded on the rhFNIII9-10-coated plates showed increased proliferation during the osteogenic differentiation. However, there was no significant difference in the alkaline phosphatase activity, calcium content and expression levels of mRNAs for alkaline phosphatase, osteopontin, cbfa-1, and type I collagen of hMSCs seeded on the rhFNIII9-10-coated plates. CONCLUSION: rhFNIII9-10 stimulates hMSCs adhesion and increases hMSCs proliferation during the osteogenic differentiation. Although osteogenic differentiation is not promoted, adsorption of rhFNIII9-10 onto appropriate biomaterials can enhance integrin-mediated hMSCs adhesion and proliferation. This biomolecular engineering strategy represents a robust approach to increase biofunctional activity and integrin specificity of hMSCs.